133 related articles for article (PubMed ID: 37662410)
1. Human plasma cells engineered to secrete bispecifics drive effective
Hill TF; Narvekar P; Asher G; Camp N; Thomas KR; Tasian SK; Rawlings DJ; James RG
bioRxiv; 2023 Aug; ():. PubMed ID: 37662410
[TBL] [Abstract][Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
[TBL] [Abstract][Full Text] [Related]
5. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
6. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
8. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
9. Large-cohort humanized NPI mice reconstituted with CD34
Xu X; Gu H; Li H; Gao S; Shi X; Shen J; Li B; Wang H; Zheng K; Shao Z; Cheng P; Cha Z; Peng S; Nie Y; Li Z; Guo S; Qian B; Jin G
FASEB J; 2022 Apr; 36(4):e22244. PubMed ID: 35262964
[TBL] [Abstract][Full Text] [Related]
10. Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B; Ramírez-Fernández Á; Bueno C; Argemí-Muntadas L; Fuentes P; Aguilar-Sopeña Ó; Gutierrez-Agüera F; Zanetti SR; Tapia-Galisteo A; Díez-Alonso L; Segura-Tudela A; Castellà M; Marzal B; Betriu S; Harwood SL; Compte M; Lykkemark S; Erce-Llamazares A; Rubio-Pérez L; Jiménez-Reinoso A; Domínguez-Alonso C; Neves M; Morales P; Paz-Artal E; Guedan S; Sanz L; Toribio ML; Roda-Navarro P; Juan M; Menéndez P; Álvarez-Vallina L
Cancer Immunol Res; 2022 Apr; 10(4):498-511. PubMed ID: 35362043
[TBL] [Abstract][Full Text] [Related]
11. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
12. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
13. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
14. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
15. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
17. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
19. Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody.
Li W; Fan D; Yang M; Yan Y; Shi R; Cheng J; Li Z; Zhang M; Wang J; Xiong D
Hum Gene Ther; 2013 Aug; 24(8):751-60. PubMed ID: 23879717
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
